US giant Johnson & Johnson (J&J; NYSE: JNJ) announced the termination of the Phase III VENTURA development program assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD). The decision was influenced by the insufficient efficacy of aticaprant in the target population.
Safety and Future Exploration
While the data confirmed the safety and good tolerability of aticaprant with no new safety signals observed, the lack of efficacy has led to its discontinuation for this indication. However, J&J has stated that aticaprant will be explored in other areas of high unmet need, given its promising mechanism. Full analyses from the VENTURA development program are currently underway and will be shared at a future medical meeting.-Fineline Info & Tech
Leave a Reply